Management of Lupus Flare

Initial Assessment and Treatment Approach

The management of a lupus flare requires prompt treatment with glucocorticoids as the cornerstone therapy, along with appropriate immunosuppressive agents based on organ involvement and severity, with the goal of achieving disease remission while minimizing long-term steroid exposure 1, 2
Determine if the flare is a new presentation or a relapse of previously controlled disease, as management strategies are generally similar for both scenarios 1
Consider a kidney biopsy if diagnosis of flare remains uncertain, especially to distinguish active disease from chronic damage 1
Treatment should be tailored based on the severity of organ involvement 3, previous treatment response 4, and presence of comorbidities 5, 2

For severe or organ-threatening flares, intravenous methylprednisolone pulses (250-500 mg/day for up to 3 days) followed by oral prednisone may be used 5, 6
Initial oral prednisone dosing based on severity: high-dose (0.8-1.0 mg/kg/day), moderate-dose (0.6-0.7 mg/kg/day), or reduced-dose (0.5-0.6 mg/kg/day) 5, 6
Aim to reduce prednisone to ≤7.5 mg/day as quickly as possible, and preferably lower 7, 8

Mycophenolate mofetil (MMF) regimen: initial therapy based on severity, maintenance phase 750-1000 mg twice daily, and continue for ≥36 months total duration 5, 8
Cyclophosphamide may be considered for severe organ-threatening disease or as rescue therapy 5, 3
Calcineurin inhibitors (voclosporin, tacrolimus, cyclosporine) may be considered for patients with preserved kidney function and nephrotic-range proteinuria 6
Belimumab may be considered as part of triple immunosuppressive regimen with glucocorticoids and either MPAA or reduced-dose cyclophosphamide 6
Rituximab may be considered for patients with persistent disease activity or inadequate response to initial standard therapy 6

If Thrombotic Microangiopathy (TMA) is present with lupus flare, manage according to underlying etiology, including testing for ADAMTS13 activity and antibodies, and antiphospholipid antibodies 1
Hydroxychloroquine is recommended for all patients with SLE (unless contraindicated) at a dose not exceeding 5 mg/kg real body weight 3
Early initiation of immunosuppressive agents can expedite tapering/discontinuation of glucocorticoids 3
Consider preemptive treatment in patients with serological activity (rising anti-dsDNA, decreasing complement) 1

Assess response based on reduction in clinical symptoms 8, improvement in laboratory parameters (complement levels, anti-dsDNA antibodies) 1, and reduction in proteinuria to <0.5 g/day and stabilization/improvement of kidney function 5, 10
Complete response definitions include reduction in proteinuria <0.5 g/g, stabilization or improvement in kidney function, and resolution of extrarenal manifestations 5

Prolonged glucocorticoid exposure is associated with significant organ damage and morbidity 7, 8
Abrupt withdrawal of glucocorticoids in patients on long-term therapy may lead to withdrawal symptoms that mimic disease flare 7, 8
Patients with low mycophenolic acid exposure are at higher risk for disease flares; consider therapeutic drug monitoring in selected cases 8
Immunosuppression withdrawal too early increases risk of relapse; maintain for at least 36 months in proliferative lupus nephritis 8, 9